Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 4, 2006, Pages 471-480

  De Sanctis, Vincenzo ^a   Roos, Malgorzata ^b   Gasser, Theo ^b   Fortini, Monica ^a   Raiola, Giuseppe ^c   Galati, Maria Concetta ^c   Nicoletti, M Caruso ^d   Ponzi, G ^e   Gamberini, M R ^a   Pedretti, S ^a   Corciulo, N ^e   Forni, G L ^e   Cilla, V ^f   Meo, A ^g   Malizia, R ^h   D'Ascola, G ⁱ   Ciaccio, C ⁱ   Gerardi, C ⁱ   Mangiagli, A ^j   Pintor, C ^k  

^a S ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c PUGLIESE CIACCIO HOSPITAL   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e Department of Paediatrics ^*  (Italy)

^f Thalassaemia Centre   (Italy)

^g UNIVERSITY OF MESSINA   (Italy)

^h Thalassaemia Centre   (Italy)

ⁱ Centro Microcitemia   (Italy)

^j Thalassaemia Service   (Italy)

^k UNIVERSITY OF CAGLIARI   (Italy)

more..

Author keywords

Chelation therapy; Endocrine complications; Growth; thalassaemia major

Indexed keywords

CALCITRIOL; DEFEROXAMINE; DEFEROXAMINE MESYLATE; IRON; RECOMBINANT GROWTH HORMONE; SEX HORMONE;

ADOLESCENT; ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DELAYED PUBERTY; EARLY INTERVENTION; ENDOCRINE FUNCTION; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; IRON CHELATION; IRON OVERLOAD; ITALY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; PATIENT COMPLIANCE; RANK SUM TEST; SEXUAL MATURATION; STANDARD; STATISTICAL ANALYSIS; THALASSEMIA MAJOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33646823167     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kattamis C. Epidemiology of chronic diseases in adolescence in Mediterranean populations. Riv Ital Med Adolesc 2004; 2: 47-52.
2. Olivieri N. The β-thalassaemias. N Engl J Med 1999; 341: 99-109.
3. Wonke B, Davies S. Recent development in the clinical management of pediatric haemoglobinopathies. Curr Opin Pediatr 1991; 3: 95-98.
4. Giardina PJ, Grady RW. Chelation therapy in β thalassaemia: the benefits and limitations of desferrioxamine. Sem Hematol 1995; 4: 304-312.
5. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36.
6. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG. Continuous subcutaneous administration of desferrioxamine in patients with iron overload. N Engl J Med 1997; 2: 310-317.
7. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 3rd Ed. Oxford: Blackwell Scientific, 1981.
8. Tanner JM. Growth at Adolescence, 2nd Ed. Oxford: Blackwell Science, 1973; 32.
9. Zachmann M, Prader A, Kind HP, Hafliger H, Budlinger H. Testicular volume during adolescence: cross-sectional and longitudinal studies. Helv Paediat Acta 1974; 29: 61-72.
10. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998; 21 (Suppl): S5-S19.
11. Arbelle JE, Porath A. Practice guidelines for the detection and management of thyroid dysfunction. A comparative review of the recommendations. Clin Endocrinol 1999; 51: 11-18.
12. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol 1995; 42: 581-586.
13. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalise likelihood. Stat Med 1992; 11: 1305-1319.
14. Prader A, Largo RH, Molinari L, Issler C. Physical growth of Swiss children from birth to 20 years of age. Helv Paediat Acta 1989; 52 (Suppl): 1-125.
15. Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, Chiarelli F, Pasquino AM, Tonini G, Vanelli M. Italian cross-sectional growth charts for height, weight and BMI (6-20y). Eur J Clin Nutr 2002; 56: 171-180.
16. Castellino N, Lupo E, Petri A, Rapa A, Bellone S, Strigni L, Vercellotti A, Cavallone A, Bona G. Secular trend dell'esordio puberale in una popolazione del Nord Italia. Minerva Pediatr 2001; 53: 487.
17. Benso L, Lorenzino C, Maggia MC, Barotto M, Pastorin L. Valutazione longitudinale dell'età al menarca nelle ragazze torinesi. Riv Ital Ped 1992; 17: 529-534.
18. Economidou J. Problems related to treatment of beta-thalassaemia major. Pediatrician 1982; 11: 157-177.
19. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in β-thalassaemia major in a developing country. J Pediatr Endocrinol Metab 2000; 13: 651-656.
20. Capra L, Atti G, De Sanctis V, Candini GC. Glucose tolerance and chelation therapy in patients with thalassaemia major. Haematologica 1983; 68: 63-67.
21. De Sanctis V, Vullo C, Bagni B, Chiccoli L. Hypoparathyroidism in beta-thalassaemia major. Acta Haematol 1992; 88: 105-108.
22. Oerter KE, Kamp GA, Munson PJ, Nienhuis AW, Cassorla FG, Manasco PK. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab 1993; 76: 357-361.
23. De Sanctis V, Atti G, Banin P, Orzincolo C, Cavallini AR, Patti D, Vullo C. Growth in thalassaemia major. Acta Med Auxol 1991; 23: 29-36.
24. De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B. Effect of different treatment regimes on linear growth and final height in β thalassaemia major. Clin Endocrinol 1994; 40: 791-798.
25. Bergeron C, Kovacs K. Pituitary siderosis. Am J Pathol 1978; 93: 295-306.
26. Saenger P, Schwartz E, Markenson AL, Graziano JH, Levine LS, New MI, Hilgartner MW. Depressed serum somatomedin in β-thalassaemia. J Pediatr 1980; 96: 214-218.
27. De Sanctis V, Urso L. Clinical experience with growth hormone treatment in patients with β-thalassaemia major. Biodrugs 1999; 11: 79-85.
28. De Sanctis V, Caruso Nicoletti M, Pintor C, Raiola G. Proposta di linee guida per la diagnosi ed il trattamento delle complicanze endocrine nel paziente talassemico. Riv Ital Ped 1999; 25: 1132-1137.
29. De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M. Desferrioxamine-induced growth retardation in patients with thalassaemia major. J Pediatr 1988; 113: 661-669.
30. Benso L, Gambotto S, Patorin L, Signorile F, Tanner JM. Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassaemic children. Eur J Pediat 1995; 154: 205-208.
31. Mangiagli A, De Sanctis V, Campisi S, Di Silvestro G, Urso L. Treatment with deferiprone (L1) in a thalassaemic patient with bone lesions due to desferrioxamine. J Pediatr Endocrinol Metab 2000; 13: 677-680.
32. Fosburg MT, Nathan D. Treatment of Cooley's anaemia. Blood 1990; 76: 435-444.
33. Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T. High prevalence of diabetes mellitus among adult beta-thalassaemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1999; 11: 1033-1036.
34. Skuse D. Psychosocial adversity and impaired growth: in search of causal mechanisms. In: Williams P, Wilkinson G, Rawnsley K, eds. The Scope of Epidemiological Psychiatry, Essays in Honour of Michael Shepherd. London: Routledge, 1989; 240-263.